Aspirin Effectiveness in Coronary Artery Disease Patients in Ireland
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 500
- 试验地点
- 1
- 主要终点
- Percentage of patients with non-response to aspirin
研究概览
简要总结
Aspirin is an effective medicine for prevention of heart attacks in patients with coronary artery disease and works by preventing clots from forming. In previous studies aspirin has been found to be ineffective in between 2% and 65% of patients but none of these studies have looked specifically at coronary artery disease patients in Ireland. This study is being done to identify the percentage of patients in Ireland whose aspirin is not working effectively and help identify factors that could be used to target interventions to increase aspirin's effectiveness in Irish patients.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 18 years or older
- •Patients with documented coronary artery disease
- •Current treatment with any dose of aspirin daily for a minimum of 3 months
- •Able to provide written informed consent based on competent mental status
排除标准
- •Myocardial infarction, unstable angina or stroke during the preceding three months
- •Platelet count <125,000/mm
- •Known haematological disorders
- •Active malignancy on current chemotherapy or a recent diagnosis of cancer
结局指标
主要结局
Percentage of patients with non-response to aspirin
时间窗: Following a minimum of 3 months of daily aspirin use
Prevalence of non-response to aspirin in coronary artery disease patients in Ireland by measurement of serum thromboxane B2
次要结局
未报告次要终点
研究者
Prof Dermot Kenny
Prof. Dermot Kenny
Royal College of Surgeons, Ireland